GlassScriptPhysician profile
Emma Lind
NPI 1881206779
$1,472.96
in general payments reported to CMS, 2019-2025
15 companies · $557 in 2025
The $557 reported for 2025 was more than what 93% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.49 · 2022: $128 · 2023: $298 · 2024: $448 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $588.42 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Synclara Cough System, Hillrom - Volara System |
| Vertex Pharmaceuticals Incorporated | $193.04 | 2021-2025 | Trikafta |
| Aimmune Therapeutics, INC. | $173.49 | 2024-2025 | Zenpep |
| Digestive Care, INC. | $115.22 | 2024-2025 | Pertzye |
| Glaxosmithkline, LLC. | $70.21 | 2024-2025 | Nucala |
| Nestle Healthcare Nutrition INC. | $68.02 | 2023 | |
| Madrigal Pharmaceuticals | $41.90 | 2024 | Resmetirom |
| Sobi, INC | $41.19 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.34 | 2024 | Eohilia |
| Masimo Corporation | $32.34 | 2022 | |
| Chiesi USA, INC. | $26.54 | 2022 | |
| Viatris Specialty LLC | $24.43 | 2025 | Tobi Podhaler |
| Alcresta Therapeutics, INC. | $24.14 | 2023 | Relizorb |
| Vivus LLC | $21.62 | 2021 | |
| Genentech USA, INC. | $18.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Lind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.